• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Selective N-Terminal BET Bromodomain Inhibitors by Targeting Non-Conserved Residues and Structured Water Displacement*.选择性靶向非保守残基和结构水置换的 N 端 BET 溴结构域抑制剂*。
Angew Chem Int Ed Engl. 2021 Jan 18;60(3):1220-1226. doi: 10.1002/anie.202008625. Epub 2020 Nov 18.
2
Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.BRD4 的共价片段筛选鉴定了一个与乙酰赖氨酸结合位点正交的配体结合位点。
ACS Chem Biol. 2020 Apr 17;15(4):1036-1049. doi: 10.1021/acschembio.0c00058. Epub 2020 Mar 23.
3
A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes.基于结构的设计方法生成高亲和力 BRD4 D1 选择性化学探针。
J Med Chem. 2022 Feb 10;65(3):2342-2360. doi: 10.1021/acs.jmedchem.1c01779. Epub 2022 Jan 10.
4
Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader.一种靶向N端BRD4溴结构域的降解剂的开发。
ACS Med Chem Lett. 2022 Sep 29;13(10):1621-1627. doi: 10.1021/acsmedchemlett.2c00300. eCollection 2022 Oct 13.
5
Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.双重激酶-溴结构域抑制剂的 N 端溴结构域和额外结构域家族选择性的分子基础。
J Med Chem. 2018 Oct 25;61(20):9316-9334. doi: 10.1021/acs.jmedchem.8b01248. Epub 2018 Oct 16.
6
4-Methyl-1,2,3-Triazoles as -Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity.4-甲基-1,2,3-三唑作为乙酰赖氨酸类似物,提供了强效的 BET 溴结构域抑制剂,具有改善的选择性。
J Med Chem. 2021 Jul 22;64(14):10497-10511. doi: 10.1021/acs.jmedchem.1c00933. Epub 2021 Jul 8.
7
Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.发现并鉴定 BRDT 的溴结构域 2 特异性抑制剂。
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9). doi: 10.1073/pnas.2021102118.
8
Discovery of Benzo[]indol-2(1)-ones and Pyrrolo[4,3,2-]quinolin-2(1)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis.苯并[吲哚-2(1H)-酮]和吡咯并[4,3,2-de]喹啉-2(1H)-酮作为溴结构域和额外末端结构域(BET)抑制剂的发现,对第一个溴结构域具有选择性,对急性痛风性关节炎具有潜在的高效性。
J Med Chem. 2019 Dec 26;62(24):11080-11107. doi: 10.1021/acs.jmedchem.9b01010. Epub 2019 Dec 13.
9
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.选择性抑制前列腺癌中 BET 蛋白的 BD2 溴结构域。
Nature. 2020 Feb;578(7794):306-310. doi: 10.1038/s41586-020-1930-8. Epub 2020 Jan 22.
10
Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.新型小分子诱导的溴结构域和末端(BET)溴结构域蛋白 BRD4 和 BRD2 选择性降解的发现及其细胞效力。
Bioorg Med Chem. 2020 Jan 1;28(1):115181. doi: 10.1016/j.bmc.2019.115181. Epub 2019 Nov 11.

引用本文的文献

1
Macrocyclic dihydropyridine analogs as pan-BET BD2-preferred inhibitors.作为泛BET BD2优先抑制剂的大环二氢吡啶类似物。
Eur J Med Chem. 2025 Jun 5;290:117504. doi: 10.1016/j.ejmech.2025.117504. Epub 2025 Mar 16.
2
Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.基于结构的选择性溴结构域和末端外溴结构域化学探针的设计。
J Med Chem. 2023 Dec 14;66(23):15728-15749. doi: 10.1021/acs.jmedchem.3c00906. Epub 2023 Nov 15.
3
Selectivity Mechanism of Pyrrolopyridone Analogues Targeting Bromodomain 2 of Bromodomain-Containing Protein 4 from Molecular Dynamics Simulations.基于分子动力学模拟的吡咯并吡啶酮类似物靶向含溴结构域蛋白4的溴结构域2的选择性机制
ACS Omega. 2023 Sep 6;8(37):33658-33674. doi: 10.1021/acsomega.3c03935. eCollection 2023 Sep 19.
4
Angiocrine Signaling in Sinusoidal Health and Disease.窦状隙的血管生成信号在健康和疾病中的作用
Semin Liver Dis. 2023 Aug;43(3):245-257. doi: 10.1055/a-2128-5907. Epub 2023 Jul 13.
5
Bromodomain inhibitors and therapeutic applications.溴结构域抑制剂及其治疗应用。
Curr Opin Chem Biol. 2023 Aug;75:102323. doi: 10.1016/j.cbpa.2023.102323. Epub 2023 May 17.
6
Targeting bromodomain-containing proteins: research advances of drug discovery.靶向含溴结构域蛋白:药物研发的研究进展
Mol Biomed. 2023 May 5;4(1):13. doi: 10.1186/s43556-023-00127-1.
7
Recent progress and structural analyses of domain-selective BET inhibitors.近期结构分析领域选择性 BET 抑制剂的研究进展。
Med Res Rev. 2023 Jul;43(4):972-1018. doi: 10.1002/med.21942. Epub 2023 Mar 27.
8
Accounting for Solvation Correlation Effects on the Thermodynamics of Water Networks in Protein Cavities.考虑溶剂化相关效应对蛋白质腔中水分子网络热力学的影响。
J Chem Inf Model. 2023 Mar 27;63(6):1794-1805. doi: 10.1021/acs.jcim.2c01610. Epub 2023 Mar 14.
9
Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader.一种靶向N端BRD4溴结构域的降解剂的开发。
ACS Med Chem Lett. 2022 Sep 29;13(10):1621-1627. doi: 10.1021/acsmedchemlett.2c00300. eCollection 2022 Oct 13.
10
A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes.基于结构的设计方法生成高亲和力 BRD4 D1 选择性化学探针。
J Med Chem. 2022 Feb 10;65(3):2342-2360. doi: 10.1021/acs.jmedchem.1c01779. Epub 2022 Jan 10.

本文引用的文献

1
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.基于结构的溴结构域和末端结构域(BET)抑制剂设计,选择性针对 N 端溴结构域,保留抗炎和抗增殖表型。
J Med Chem. 2020 Sep 10;63(17):9020-9044. doi: 10.1021/acs.jmedchem.0c00566. Epub 2020 Aug 3.
2
New inhibitors for the BPTF bromodomain enabled by structural biology and biophysical assay development.基于结构生物学和生物物理检测方法开发的新型 BPTF 溴结构域抑制剂。
Org Biomol Chem. 2020 Jul 15;18(27):5174-5182. doi: 10.1039/d0ob00506a.
3
Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.发现具有口服生物利用度的色酮衍生物作为强效和选择性 BRD4 抑制剂:骨架跃迁、优化和药理学评价。
J Med Chem. 2020 May 28;63(10):5242-5256. doi: 10.1021/acs.jmedchem.0c00035. Epub 2020 Apr 22.
4
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.选择性抑制前列腺癌中 BET 蛋白的 BD2 溴结构域。
Nature. 2020 Feb;578(7794):306-310. doi: 10.1038/s41586-020-1930-8. Epub 2020 Jan 22.
5
Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors.系统地减轻基于三唑的溴结构域和额外末端结构域(BET)抑制剂的p38α活性
ACS Med Chem Lett. 2019 Aug 2;10(9):1296-1301. doi: 10.1021/acsmedchemlett.9b00227. eCollection 2019 Sep 12.
6
Time series modeling of cell cycle exit identifies Brd4 dependent regulation of cerebellar neurogenesis.细胞周期退出的时间序列建模确定了 Brd4 对小脑神经发生的调控作用。
Nat Commun. 2019 Jul 10;10(1):3028. doi: 10.1038/s41467-019-10799-5.
7
Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.双重激酶-溴结构域抑制剂的 N 端溴结构域和额外结构域家族选择性的分子基础。
J Med Chem. 2018 Oct 25;61(20):9316-9334. doi: 10.1021/acs.jmedchem.8b01248. Epub 2018 Oct 16.
8
Large-scale analysis of water stability in bromodomain binding pockets with grand canonical Monte Carlo.使用巨正则蒙特卡罗方法对溴结构域结合口袋中的水稳定性进行大规模分析。
Commun Chem. 2018 Apr 5;1. doi: 10.1038/s42004-018-0019-x.
9
The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors.ZA 通道水介导相互作用在设计溴结构域选择性 BET 抑制剂中的作用。
J Mol Graph Model. 2018 May;81:197-210. doi: 10.1016/j.jmgm.2018.03.005. Epub 2018 Mar 22.
10
Click chemistry enables preclinical evaluation of targeted epigenetic therapies.点击化学可实现靶向表观遗传疗法的临床前评估。
Science. 2017 Jun 30;356(6345):1397-1401. doi: 10.1126/science.aal2066. Epub 2017 Jun 15.

选择性靶向非保守残基和结构水置换的 N 端 BET 溴结构域抑制剂*。

Selective N-Terminal BET Bromodomain Inhibitors by Targeting Non-Conserved Residues and Structured Water Displacement*.

机构信息

Department of Chemistry, University of Minnesota-Twin Cities, 207 Pleasant St. SE, Minneapolis, MN, 55455, USA.

Department of Medicinal Chemistry, University of Minnesota-Twin Cities, 2231 6th St. SE, Minneapolis, MN, 55455, USA.

出版信息

Angew Chem Int Ed Engl. 2021 Jan 18;60(3):1220-1226. doi: 10.1002/anie.202008625. Epub 2020 Nov 18.

DOI:10.1002/anie.202008625
PMID:32975004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7855888/
Abstract

Bromodomain and extra-terminal (BET) family proteins, BRD2-4 and T, are important drug targets; however, the biological functions of each bromodomain remain ill-defined. Chemical probes that selectively inhibit a single BET bromodomain are lacking, although pan inhibitors of the first (D1), and second (D2), bromodomain are known. Here, we develop selective BET D1 inhibitors with preferred binding to BRD4 D1. In competitive inhibition assays, we show that our lead compound is 9-33 fold selective for BRD4 D1 over the other BET bromodomains. X-ray crystallography supports a role for the selectivity based on reorganization of a non-conserved lysine and displacement of an additional structured water in the BRD4 D1 binding site relative to our prior lead. Whereas pan-D1 inhibitors displace BRD4 from MYC enhancers, BRD4 D1 inhibition in MM.1S cells is insufficient for stopping Myc expression and may lead to its upregulation. Future analysis of BRD4 D1 gene regulation may shed light on differential BET bromodomain functions.

摘要

溴结构域和末端(BET)家族蛋白,BRD2-4 和 T,是重要的药物靶点;然而,每个溴结构域的生物学功能仍未确定。尽管已经有针对第一(D1)和第二(D2)溴结构域的泛 BET 抑制剂,但缺乏选择性抑制单个 BET 溴结构域的化学探针。在这里,我们开发了选择性 BET D1 抑制剂,优先与 BRD4 D1 结合。在竞争性抑制测定中,我们表明我们的先导化合物对 BRD4 D1 的选择性是其他 BET 溴结构域的 9-33 倍。X 射线晶体学支持基于非保守赖氨酸的重排和 BRD4 D1 结合位点中额外结构水的置换的选择性作用,与我们之前的先导化合物相比。虽然泛 D1 抑制剂可将 BRD4 从 MYC 增强子中置换出来,但在 MM.1S 细胞中抑制 BRD4 D1 不足以阻止 Myc 表达,并且可能导致其上调。对 BRD4 D1 基因调控的进一步分析可能阐明 BET 溴结构域功能的差异。